๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

New perspectives on the molecular pharmacology of affective disorders

โœ Scribed by Fridolin Sulser


Publisher
Springer-Verlag
Year
1989
Tongue
English
Weight
948 KB
Volume
238
Category
Article
ISSN
1433-8491

No coin nor oath required. For personal study only.

โœฆ Synopsis


Research with antidepressants has emphasized the importance of a delayed deamplification of the linked serotonin (5HT)/norepinephrine (NE) receptor coupled adenylate cyclase system in brain. The basic phenomena of regulation of receptor number and function of the beta adrenoceptor linked adenylate cyclase system in brain are well established, with NE regulating beta adrenoceptors in the high agonist affinity conformation (linked to adenylate cyclase and down-regulated by antidepressants), and with 5HT regulating those receptors in the low agonist affinity conformation. The biochemical effector systems of NE and 5HT are discussed and it is concluded that the final common pathway of signal transduction is protein kinase mediated phosphorylation of cellular proteins. Glucocorticoid receptors are located in the perikarya of aminergic cell bodies and may exert their effects by modifying the genomic expression of the diffusely projecting stress-responsive monoamine systems. The molecular neurobiology of beta adrenoceptors, with its implication for genetic and immunologic investigations, is briefly discussed and further research on stimulus-transcription coupling and regulation of gene expression in brain is suggested as an exciting new direction in central receptor research relevant to the psychopharmacology of affective and other disorders.


๐Ÿ“œ SIMILAR VOLUMES


New perspectives in managing myeloprolif
โœ Gunnar Birgegรฅrd ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 71 KB

## Abstract Risk stratification is the basis for treatment decisions in the chronic myeloproliferative disorders, and in addition to the three established risk factors of previous thrombosis, age and platelets >1500โ€‰ร—โ€‰10^9^, cardiovascular risk factors should be addressed. In addition, premorbidity

Setting New Standards for the Pharmacolo
โœ R. KUMAR ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 161 KB ๐Ÿ‘ 2 views

Three drugs are currently licensed for the treatment of panic disorder: the benzodiazepine, alprazolam; the tricyclic antidepressant, clomipramine; and, most recently, the selective serotonin reuptake inhibitor, paroxetine. Alprazolam and clomipramine are eective in the treatment of panic disorder,